Drug Overview
Tecentriq (atezolizumab; Roche/Chugai) is a fully humanized monoclonal antibody that targets programmed death-ligand 1 (PD-L1). PD-L1 is expressed on the surface of antigen-presenting cells and some tumor cells. PD-L1 binds to programmed death-1 (PD-1) co-inhibitory receptors which are expressed on the surface of T cells after T-cell activation.
The receptor ligand interaction produces inhibitory signals which regulate T-cell activation and promote immune tolerance, which favors tumor progression. By blocking the PD-L1/PD-1 interaction, Tecentriq enables T-cell activation and allows the immune system to mount a more effective anti-tumor response.
Tecentriq (atezolizumab; Roche/Chugai) is a fully humanized monoclonal antibody that targets programmed death-ligand 1 (PD-L1). PD-L1 is expressed on the surface of antigen-presenting cells and some tumor cells. PD-L1 binds to programmed death-1 (PD-1) co-inhibitory receptors which are expressed on the surface of T cells after T-cell activation.
The receptor ligand interaction produces inhibitory signals which regulate T-cell activation and promote immune tolerance, which favors tumor progression. By blocking the PD-L1/PD-1 interaction, Tecentriq enables T-cell activation and allows the immune system to mount a more effective anti-tumor response.
Table of Contents
OVERVIEW
- Drug Overview
- Product Profiles
- Tecentriq : Hepatocellular carcinoma (HCC)
- Tecentriq : Renal cell carcinoma (RCC)
- Tecentriq : Non-small cell lung cancer (NSCLC)
- Tecentriq : Melanoma
- Tecentriq : Prostate cancer
- Tecentriq : Colorectal cancer (CRC)
- Tecentriq : Ovarian cancer
- Tecentriq : Bladder cancer
- atezolizumab : Breast cancer: triple-negative
LIST OF FIGURES
Figure 11: The author's drug assessment summary of Tecentriq for melanoma
Figure 12: The author's drug assessment summary of Tecentriq for melanoma
Figure 13: Tecentriq sales for melanoma across the US and five major EU markets, by country, 2017–26
Figure 14: Tecentriq for prostate cancer – SWOT analysis
Figure 15: The author's drug assessment summary of Tecentriq for prostate cancer
Figure 6: The author's drug assessment summary of Tecentriq for RCC
Figure 16: The author's drug assessment summary of Tecentriq for prostate cancer
Figure 17: Tecentriq for colorectal cancer – SWOT analysis
Figure 9: The author's drug assessment summary for Tecentriq in non-small cell lung cancer
Figure 10: The author's drug assessment summary for Tecentriq in non-small cell lung cancer
Figure 18: The author's drug assessment summary of Tecentriq for colorectal cancer
Figure 19: Tecentriq sales for colorectal cancer across the US and five major EU markets, by country, 2016–25
Figure 20: Tecentriq for ovarian cancer – SWOT analysis
Figure 21: The author's drug assessment of Tecentriq for ovarian cancer
Figure 22: The author's drug assessment of Tecentriq for ovarian cancer
Figure 23: Tecentriq for urothelial bladder cancer – SWOT analysis
Figure 24: The author's drug assessment summary for Tecentriq in urothelial bladder cancer
Figure 25: The author's drug assessment summary for Tecentriq in urothelial bladder cancer
Figure 26: Atezolizumab for triple-negative breast cancer – SWOT analysis
Figure 20: The author's drug assessment summary of Tecentriq for colorectal cancer
Figure 27: The author's drug assessment summary of atezolizumab for triple-negative breast cancer
Figure 28: The author's drug assessment summary of atezolizumab for triple-negative breast cancer
Figure 23: The author's drug assessment of Tecentriq for ovarian cancer
Figure 24: The author's drug assessment of Tecentriq for ovarian cancer
Figure 25: Tecentriq for urothelial bladder cancer – SWOT analysis
Figure 1: The author's assessment summary of key marketed and pipeline drugs for HCC
Figure 27: The author's drug assessment summary for Tecentriq in urothelial bladder cancer
Figure 2: HCC sales in the US, 2018–27
Figure 3: HCC sales in Japan, 2018–27
Figure 30: The author's drug assessment summary of atezolizumab for triple-negative breast cancer
Figure 12: The author's drug assessment summary of Tecentriq for melanoma
Figure 13: Tecentriq sales for melanoma across the US and five major EU markets, by country, 2017–26
Figure 14: Tecentriq for prostate cancer – SWOT analysis
Figure 15: The author's drug assessment summary of Tecentriq for prostate cancer
Figure 6: The author's drug assessment summary of Tecentriq for RCC
Figure 16: The author's drug assessment summary of Tecentriq for prostate cancer
Figure 17: Tecentriq for colorectal cancer – SWOT analysis
Figure 9: The author's drug assessment summary for Tecentriq in non-small cell lung cancer
Figure 10: The author's drug assessment summary for Tecentriq in non-small cell lung cancer
Figure 18: The author's drug assessment summary of Tecentriq for colorectal cancer
Figure 19: Tecentriq sales for colorectal cancer across the US and five major EU markets, by country, 2016–25
Figure 20: Tecentriq for ovarian cancer – SWOT analysis
Figure 21: The author's drug assessment of Tecentriq for ovarian cancer
Figure 22: The author's drug assessment of Tecentriq for ovarian cancer
Figure 23: Tecentriq for urothelial bladder cancer – SWOT analysis
Figure 24: The author's drug assessment summary for Tecentriq in urothelial bladder cancer
Figure 25: The author's drug assessment summary for Tecentriq in urothelial bladder cancer
Figure 26: Atezolizumab for triple-negative breast cancer – SWOT analysis
Figure 20: The author's drug assessment summary of Tecentriq for colorectal cancer
Figure 27: The author's drug assessment summary of atezolizumab for triple-negative breast cancer
Figure 28: The author's drug assessment summary of atezolizumab for triple-negative breast cancer
Figure 23: The author's drug assessment of Tecentriq for ovarian cancer
Figure 24: The author's drug assessment of Tecentriq for ovarian cancer
Figure 25: Tecentriq for urothelial bladder cancer – SWOT analysis
Figure 1: The author's assessment summary of key marketed and pipeline drugs for HCC
Figure 27: The author's drug assessment summary for Tecentriq in urothelial bladder cancer
Figure 2: HCC sales in the US, 2018–27
Figure 3: HCC sales in Japan, 2018–27
Figure 30: The author's drug assessment summary of atezolizumab for triple-negative breast cancer
LIST OF TABLES
Table 1: Recent high-impact events for Tecentriq in HCC
Table 2: Tecentriq drug profile
Table 3: Trials of Tecentriq for HCC
Table 4: Tecentriq for HCC – SWOT analysis
Table 5: Tecentriq drug profile
Table 6: Tecentriq Phase III data in RCC
Table 7: Tecentriq Phase III trials in RCC
Table 8: Tecentriq sales for RCC across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 9: Tecentriq drug profile
Table 10: Tecentriq pivotal trial data in non-small cell lung cancer
Table 11: Tecentriq late-phase trial data in non-small cell lung cancer
Table 12: Tecentriq ongoing late-phase trial data in non-small cell lung cancer
Table 13: Tecentriq sales for NSCLC across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 14: Tecentriq patient numbers for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
Table 15: Tecentriq drug profile
Table 16: Tecentriq ongoing late-phase trials in melanoma
Table 17: Tecentriq early-phase data in melanoma
Table 18: Tecentriq sales for melanoma across the US and five major EU markets, by country ($m), 2017–26
Table 19: Tecentriq patient numbers for melanoma across the US and five major EU markets, by country, 2017–26
Table 20: Tecentriq drug profile
Table 21: Tecentriq Phase III trials in prostate cancer
Table 22: Tecentriq sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 23: Tecentriq drug profile
Table 24: Tecentriq Phase III trial in colorectal cancer
Table 25: Tecentriq early-phase data in colorectal cancer
Table 26: Tecentriq sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016–25
Table 27: Patients treated with Tecentriq in the US and five major EU markets, by country, 2016–25
Table 28: Tecentriq drug profile
Table 29: Tecentriq Phase III trials in ovarian cancer
Table 30: Overview of Phase I data for Tecentriq in ovarian cancer
Table 31: Tecentriq drug profile
Table 32: Tecentriq pivotal trial data in urothelial bladder cancer
Table 33: Tecentriq ongoing late-phase trials in urothelial bladder cancer
Table 34: Atezolizumab drug profile
Table 4: HCC – current and future forecast trends
Table 36: Atezolizumab Phase Ib data in triple-negative breast cancer
Table 37: Atezolizumab Phase I data in triple-negative breast cancer
Table 2: Tecentriq drug profile
Table 3: Trials of Tecentriq for HCC
Table 4: Tecentriq for HCC – SWOT analysis
Table 5: Tecentriq drug profile
Table 6: Tecentriq Phase III data in RCC
Table 7: Tecentriq Phase III trials in RCC
Table 8: Tecentriq sales for RCC across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 9: Tecentriq drug profile
Table 10: Tecentriq pivotal trial data in non-small cell lung cancer
Table 11: Tecentriq late-phase trial data in non-small cell lung cancer
Table 12: Tecentriq ongoing late-phase trial data in non-small cell lung cancer
Table 13: Tecentriq sales for NSCLC across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 14: Tecentriq patient numbers for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
Table 15: Tecentriq drug profile
Table 16: Tecentriq ongoing late-phase trials in melanoma
Table 17: Tecentriq early-phase data in melanoma
Table 18: Tecentriq sales for melanoma across the US and five major EU markets, by country ($m), 2017–26
Table 19: Tecentriq patient numbers for melanoma across the US and five major EU markets, by country, 2017–26
Table 20: Tecentriq drug profile
Table 21: Tecentriq Phase III trials in prostate cancer
Table 22: Tecentriq sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 23: Tecentriq drug profile
Table 24: Tecentriq Phase III trial in colorectal cancer
Table 25: Tecentriq early-phase data in colorectal cancer
Table 26: Tecentriq sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016–25
Table 27: Patients treated with Tecentriq in the US and five major EU markets, by country, 2016–25
Table 28: Tecentriq drug profile
Table 29: Tecentriq Phase III trials in ovarian cancer
Table 30: Overview of Phase I data for Tecentriq in ovarian cancer
Table 31: Tecentriq drug profile
Table 32: Tecentriq pivotal trial data in urothelial bladder cancer
Table 33: Tecentriq ongoing late-phase trials in urothelial bladder cancer
Table 34: Atezolizumab drug profile
Table 4: HCC – current and future forecast trends
Table 36: Atezolizumab Phase Ib data in triple-negative breast cancer
Table 37: Atezolizumab Phase I data in triple-negative breast cancer
